StockStory
Q4 Earnings Outperformers: Labcorp (NYSE:LH) And The Rest Of The Testing & Diagnostics Services Stocks
➖
AI Sentiment
Neutral
4/10
- Home
- LH
as of 03-12-2026 3:43pm EST
$263.99
$6.44
-2.38%
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
| Founded: | 1971 | Country: | United States |
| Employees: | 70000 | City: | BURLINGTON |
| Market Cap: | 20.9B | IPO Year: | 2005 |
| Target Price: | $308.30 | AVG Volume (30 days): | 602.6K |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | Dividend Payout Frequency: | quarterly | |
| EPS: | 10.46 | EPS Growth: | 18.33 |
| 52 Week Low/High: | $209.38 - $293.72 | Next Earning Date: | N/A |
| Revenue: | $13,951,700,000 | Revenue Growth: | 7.25% |
| Revenue Growth (this year): | 8.36% | Revenue Growth (next year): | 4.73% |
| P/E Ratio: | 25.83 | Index: | |
| Free Cash Flow: | 1.2B | FCF Growth: | +10.05% |
Stock Insider Trading Activity of Laboratory Corporation of America Holdings (LH)
Schechter Adam H
Sell
President & CEO
LH Mar 3, 2026
Avg Cost/Share
$279.96
Shares
8,705
Total Value
$2,437,047.45
Owned After
80,773
SEC Form 4
van der Vaart Sandra D
Sell
EVP, Corporate Affairs
LH Feb 27, 2026
Avg Cost/Share
$284.91
Shares
547
Total Value
$155,999.54
Owned After
2,578.947
SEC Form 4
Caveney Brian J
Sell
EVP, Pres of ED, CMO & CSO
LH Feb 24, 2026
Avg Cost/Share
$286.31
Shares
1,500
Total Value
$429,457.50
Owned After
30,106.923
SEC Form 4
Wilkinson Peter J
Sell
SVP, Chief Accounting Officer
LH Feb 19, 2026
Avg Cost/Share
$277.94
Shares
666
Total Value
$185,108.04
Owned After
1,852.219
SEC Form 4
Meltzer Jonathan C
Sell
EVP, Operations
LH Feb 12, 2026
Avg Cost/Share
$290.42
Shares
87
Total Value
$25,266.54
Owned After
2,782.326
SEC Form 4
Schechter Adam H
Sell
President & CEO
LH Feb 11, 2026
Avg Cost/Share
$284.38
Shares
5,273
Total Value
$1,499,535.74
Owned After
80,773
SEC Form 4
Meltzer Jonathan C
Sell
EVP, Operations
LH Feb 10, 2026
Avg Cost/Share
$276.79
Shares
91
Total Value
$25,187.89
Owned After
2,782.326
SEC Form 4
Meltzer Jonathan C
Sell
EVP, Operations
LH Feb 9, 2026
Avg Cost/Share
$275.53
Shares
88
Total Value
$24,246.64
Owned After
2,782.326
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Schechter Adam H | LH | President & CEO | Mar 3, 2026 | Sell | $279.96 | 8,705 | $2,437,047.45 | 80,773 | |
| van der Vaart Sandra D | LH | EVP, Corporate Affairs | Feb 27, 2026 | Sell | $284.91 | 547 | $155,999.54 | 2,578.947 | |
| Caveney Brian J | LH | EVP, Pres of ED, CMO & CSO | Feb 24, 2026 | Sell | $286.31 | 1,500 | $429,457.50 | 30,106.923 | |
| Wilkinson Peter J | LH | SVP, Chief Accounting Officer | Feb 19, 2026 | Sell | $277.94 | 666 | $185,108.04 | 1,852.219 | |
| Meltzer Jonathan C | LH | EVP, Operations | Feb 12, 2026 | Sell | $290.42 | 87 | $25,266.54 | 2,782.326 | |
| Schechter Adam H | LH | President & CEO | Feb 11, 2026 | Sell | $284.38 | 5,273 | $1,499,535.74 | 80,773 | |
| Meltzer Jonathan C | LH | EVP, Operations | Feb 10, 2026 | Sell | $276.79 | 91 | $25,187.89 | 2,782.326 | |
| Meltzer Jonathan C | LH | EVP, Operations | Feb 9, 2026 | Sell | $275.53 | 88 | $24,246.64 | 2,782.326 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 17, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 17, 2026 · 100% conf.
AI Prediction SELL
1D
-0.95%
$274.03
5D
-1.80%
$271.69
20D
-1.24%
$273.24
Price: $276.67 Prob +5D: 0% AUC: 1.000
0000920148-26-000098
lh-202602170000920148false00009201482026-02-172026-02-17
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
February 17, 2026 (Date of earliest event reported)
LABCORP HOLDINGS INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware1-1135399-2588107 (State or other jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each classTrading SymbolName of exchange on which registered Common Stock, $0.10 par valueLHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits. ExhibitExhibit Name Exhibit 99.1Press Release dated February 17, 2026 issued by Labcorp titled “Labcorp Announces 2025 Fourth Quarter and Full Year Results”
Exhibit 104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LABCORP HOLDINGS INC.
Registrant
Date: February 17, 2026By:/s/ KATHRYN W. KYLE Kathryn W. Kyle Executive Vice President, Chief Legal Officer and Corporate Secretary
2025 Q3 Q3 2025 Earnings
8-K Oct 28, 2025
2025
Q3
Q3 2025 Earnings
8-KOct 28, 2025
0000920148-25-000093
lh-202510280000920148false00009201482025-10-282025-10-28
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
October 28, 2025 (Date of earliest event reported)
LABCORP HOLDINGS INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware1-1135399-2588107 (State or other jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each classTrading SymbolName of exchange on which registered Common Stock, $0.10 par valueLHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits. ExhibitExhibit Name Exhibit 99.1Press Release dated October 28, 2025 issued by Labcorp titled “Labcorp Announces 2025 Third Quarter Results”
Exhibit 104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LABCORP HOLDINGS INC.
Registrant
Date: October 28, 2025By:/s/ SANDRA D. VAN DER VAART Sandra D. van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
2025 Q2 Q2 2025 Earnings
8-K Jul 24, 2025
2025
Q2
Q2 2025 Earnings
8-KJul 24, 2025
0000920148-25-000075
lh-202507240000920148false00009201482025-07-242025-07-24
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
July 24, 2025 (Date of earliest event reported)
LABCORP HOLDINGS INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware1-1135399-2588107 (State or other jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
358 South Main Street Burlington,North Carolina27215 (Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each classTrading SymbolName of exchange on which registered Common Stock, $0.10 par valueLHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition
Item 9.01Financial Statements and Exhibits. ExhibitExhibit Name Exhibit 99.1Press Release dated July 24, 2025 issued by Labcorp titled “Labcorp Announces 2025 Second Quarter Results”
Exhibit 104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LABCORP HOLDINGS INC.
Registrant
Date: July 24, 2025By:/s/ SANDRA D. VAN DER VAART Sandra D. van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary
Latest Laboratory Corporation of America Holdings News
LH Breaking Stock News: Dive into LH Ticker-Specific Updates for Smart Investing
Zacks
Labcorp Holdings (LH) is a Top-Ranked Value Stock: Should You Buy?
➖
AI Sentiment
Neutral
5/10
Compare LH vs Leading Stocks
See how LH stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "LH Laboratory Corporation of America Holdings - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.